MultiCell Technologies works on cancer drug

LINCOLN – MultiCell Technologies Inc. says it has reached a milestone in its work to develop a drug to treat colorectal cancer, the third leading cause of death from cancer among both men and women in the United States.
MCT-475 is a patent-pending antigen presenting immunoglobulin therapeutic to be co-administered with MCT-465, another MultiCell drug. The prospective MCT-475 drug treatment has achieved pre-clinical development status.
“Previously we demonstrated that co-administration of MCT-465 with our patent pending antigen-presenting immunoglobulin therapeutic IgNP prototype completely destroyed tumors, and prevented mortality and recurrence in animal models,” said Dr. Stephen Chang, President and CEO of Multicell Technologies.
MultiCell Technologies is an integrated biopharmaceutical company committed to the development of breakthrough therapies, using a drug development program that focuses on modulation of the immune system.